retatrutide mechanism triple agonist gip glp-1 glucagon retatrutide Dosage & Titration: Complete Escalation Protocol (5-30 mg) Retatrutide vs Tirzepatide: Which Peptide

The dietary approach matters too

Early- to mid-stage trials in people with obesity (with and without type 2 diabetes) have reported substantial average weight reductions over 48 weeks at higher doses, alongside improvements in measures like waist circumference, blood lipids and liver fat in those with metabolic fatty liver disease

a direct causal link in humans has not been established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should avoid this class of medicine [16] [17] Gallbladder disease rapid weight loss can increase the risk of gallstones and gallbladder inflammation [25] [26] Diabetic retinopathy rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in people with pre-existing disease

Any retatrutide available outside of clinical trials is sourced from research suppliers and has not undergone regulatory review